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Between Life and Profit: Global Governance and the
Trilogy of Human Rights, Public Health and
Pharmaceutical Patents
Obijiofor Aginamt
The enjoyment of the highest attainable standard of health is one
of the fundamental rights of every human being without distinction
of race, religion, political belief economic or social condition.
-Constitution of the World Health Organization'
[T]heir relations in the field of trade and economic endeavour
should be conducted with a view to raising standards of living...
-Marrakesh Agreement Establishing the WTO
2
Integrative tendencies in international life, combined with the
widely imagined future of a cyber world, ensure that a global
civilization in some form will take shape.... The sort of global
civilization that is taking shape will be widely perceived, not as
fulfillment of a vision of unity and harmony, but as a dysutopian
result of globalism-from-above that is mainly constituted by
economistic ideas and pressures.
-Richard Falk3
t Ph.D., Associate Professor of Law, Carleton University, Ottawa, Canada. This
article is based on a paper I presented at a symposium, "Saving Profits, Saving Lives: A
Comprehensive Discussion of the Social, Legal, and Economic Implications of Reverse
Engineering and Parallel Importing on the Pharmaceutical Industry," organized by the
North Carolina Journal of International Law and Commercial Regulation, February 25,
2006, University of North Carolina School of Law, Chapel Hill, North Carolina. I would
like to thank E. Abena Antwi, the NCILJ symposium editor, for inviting me to the
symposium.
I World Health Org., Constitution, Preamble, July 22, 1946, http://policy.who.
int/cgi-bin/omjisapi.dll?hitsperheading=on&infobase=basicdoc&record= 1 21 &softpage
=Document42.
2 Preamble, Apr. 15, 1994, Marrakesh Agreement Establishing the World Trade
Organization, 33 I.L.M. 1125 (1994), http://www.wto.org/English/docselegal-e/04-
wtoe.htm.
3 Richard Falk, The Coming Global Civilization: Neo-Liberal or Humanist, in
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I. Prologue: Global Governance and the Unholy Alliance of
Human Rights, Public Health and Pharmaceutical Patents
At the tripartite levels of academic scholarship, national and
international public policy, and civil society activism, global
governance orthodoxies highlight the complexities of the
irreconcilable tension(s) in the interface of human rights, public
health, and pharmaceutical patents in global interdependence of
nations and peoples. The Westphalian international system, which
is anchored on the primacy of the nation-state has often been
driven by the economic and strategic interests of states, but at least
in the last two decades, "emerging global issues and institutions"
have changed the dynamics and governance architecture of the
international system in very complex ways.
The Human Immunodeficiency Virus and Acquired Immune
Deficiency Syndrome (HIV/AIDS)-a virus that decimates the
natural immune system of the human body which then leads to a
syndrome that leaves the body defenseless against opportunistic
infections-is one such emergent global issue as is the World
Trade Organization (WTO) such an emergent institution.
Tensions, often in the form of mild ideological differences, have
been a hallmark of the "anarchical international system.' '4 In the
contemporary interdependence of nations and peoples, global
governance questions surrounding HIV/AIDS and access to anti-
retroviral ("ARV") drugs, especially in developing countries, and
the globalization of intellectual property rights and norms of free-
WEERAMANTRY 15 (A. Anghie & G. Sturgess eds., 1998).
4 See generally, HEDLEY BULL, THE ANARCHICAL SOCIETY: A STUDY OF ORDER IN
WORLD POLITICS (1995).
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trade by the WTO add to these classic tensions. Sandwiched
between legal and policy issues on access to ARV treatment for
HlV/AIDS and intellectual property rights are the age-old human
rights norms recognized first in customary law, and then codified
by treaty-based international law.
With the establishment of the WTO in 1995 and the list of
agreements annexed to its constituent instrument, especially the
Trade-Related Aspects of Intellectual Property Rights Agreement
(TRIPS), 5 the discourse of the interface of human rights, public
health, and pharmaceutical patents in global economic relations
has raised recondite legal and policy issues. In this article, I strive
to contribute to the fruitful debate regarding recondite issues from
the perspective of international law and emerging perspectives in
global governance.
In what has since become a "life versus profit" debate,6 TRIPS
has firmly pitted corporate profit against vulnerable populations
who live with HIV/AIDS globally, human right to life against
intellectual property rights; and civil society groups against
transnational pharmaceutical corporations The quotations
beginning the article illustrate the two most important international
institutions whose respective multilateral mandates cut across
global health and global trade-the WTO and the World Health
Organization (WHO) have clear provisions in the preamble to their
respective constituent instruments on "raising standards of living"
and the fundamental right to the "enjoyment of the highest
5 Agreement on Trade Related Aspects of Intellectual Property Rights, Apr. 15,
1994, Marrakesh Agreement Establishing the World Trade Organization, Annex IC,
Legal Instruments-Results of the Uruguay Round, 33 I.L.M. 81 (1994).
6 To illustrate this debate, exonerating patents as a substantial barrier to ARV
treatment for AIDS, see Amir Attaran & Lee Gillespie-White, Do Patents for
Antiretroviral Drugs Constrain Access to AIDS Treatment in Africa?, 286 J. AM. MED.
ASs'N 1886, 1891 (2001) (stating that "the extreme dearth of international aid finance,
rather than patents, is most to blame for the lack of antiretroviral treatment in Africa....
Patents generally do not appear to be a substantial barrier to antiretroviral access in
Africa."). On the profit maximizing practices of pharmaceutical companies, see Caroline
Thomas, Trade Policy and the Politics of Access to Drugs, 23 THIRD WORLD Q. 251,
259 (2002) (stating that "R&D priorities are set by companies not according to public
health, but rather according to calculations about maximizing the return to shareholders.
Developing countries do not represent a lucrative market. The pharmaceutical market is
huge--over $400 billion per annum.")
7 Obijiofor Aginam, International Law and Communicable Disease, 80 BULL.
WORLD HEALTH ORG. 946,949 (2002).
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attainable standard of health."8 Despite the commonalities in these
values that touch on human dignity, why has the interface between
human rights, public health and pharmaceutical patents shifted
from humane partnership to an unholy alliance?
In an indictment of economic globalization, Richard Falk, at
the outset, challenges "integrative tendencies in international life"
to be more protective of public goods and the capacity of the
"sovereign state" to facilitate the delivery of these goods to
vulnerable populations.9  Falk's indictment is a challenge to
international scholars and global institutions to search for
viable ways to attain a humane vision of unity and harmony.
Focusing on one of the key governance frameworks of economic
globalization-the normative architecture of the WTO, especially
the TRIPS agreement, this article explores the perceived or real
marginalization of public health and human rights by the WTO.
This article is divided into five major parts. Part I gives an
overview of the tension between human rights, public health and
pharmaceutical patents in the contemporary global interdependence
of nations and peoples. Part II explores HIV/AIDS as a global
emergency. The global crisis of HIV/AIDS, its prevalence in the
less developed regions of the world, and the fact that a sizeable
percentage of HIV positive patients in developing countries cannot
afford ARV drugs poses a challenge for contemporary global
governance orthodoxies to "humanize our global order."'" In Part
III, because HIV/AIDS is a global emergency, this article explores
the interface between the WTO, TRIPS, and access to essential
medicines. How can TRIPS flexibilities be employed to save
millions of lives, especially in developing countries where the
mortality and morbidity burdens of AIDS are high? Part IV traces
the public health fingerprints in the global trade regime. Focusing
on international trade jurisprudence, this section argues that public
health imperatives as well as other public goods are marginalized
by the dogma of free trade. Part V presents the conclusion and an
agenda for the future based on policy coherence and balancing the
imperatives of human rights, public health, and trade liberalization
8 WHO, Constitution, Preamble, supra note 1; Marrakesh Agreement, supra note
2.
9 Falk, supra note 3.
10 For perspectives on humanizing the global order, see OBIORA C. OKAFOR &
OBUIOFOR AGINAM, HUMANIZING OUR GLOBAL ORDER: ESSAYS IN HONOUR OF IVAN
HEAD (2003).
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within the mandates of the WHO, and the WTO.
II. AIDS as a Global Emergency
Our response to AIDS has so far been a failure. There has been
scientific progress, but with few dividends for people living with
poverty as well as HIV. In most of sub-Saharan Africa, they
have access to neither prevention nor treatment. Three million
deaths this year, and not yet counted millions of new infections,
bespeak massive failure.
-Paul Farmer 
I
Although HIV/AIDS has become a global emergency with
over 45 million cases globally since 1980,12 the disproportionate
infection rate and prevalence of the mortality and morbidity
burdens of the disease between the developing and developed
regions of the world raises legal, moral, and ethical questions
about the global framework for its prevention, control, and most
importantly, treatment. 3 Although the HIV/AIDS pandemic is
global with the number of infections rising in almost every region
of the world, the Joint United Nations Programme on HIV/AIDS
(UNAIDS) and the World Health Organization estimate that
Africa
remains by far the worst-affected region, with 25.4 million [23.4
million-28.4 million] people living with HIV at the end of
2004, compared to 24.4 million [22.5 million- 27.3 million] in
2002. Just under two thirds (64%) of all people living with HIV
are in sub-Saharan Africa, as are more than three quarters (76%)
of all women living with HIV.
14
Southern Africa, according to the UNAIDS/WHO study,
"remains the worst affected sub-region in the world, with data
from selected antenatal clinics in urban centers showing HIV
prevalence surpassing 25%, having risen sharply from around 5%
1I Editorial, AIDS as a Global Emergency, 81 BULL. WORLD HEALTH ORG 699
(2003).
12 See generally UNAIDS, WHO, REPORT ON THE GLOBAL HIV/AIDS EPIDEMIC
2002 (2002).
13 Nicholas Eberstadt, The Future of AIDS, Vol.81 No.6 FOREIGN AFF. 22 (2002)
(stating that the HIV/AIDS pandemic, although global, is overwhelmingly concentrated
in the least developed regions of the world, and that infection will be rapid in Eurasia
driven by the spread of the disease in the region's three largest countries: China, India
and Russia).
14 UNAIDS/WHO, AIDS EPIDEMIC UPDATE 2004 at 2 (2004).
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in 1990."" 5 Very high HIV prevalence, often exceeding 30%
among pregnant women, is still being recorded in four Southern
African countries: Botswana, Lesotho, Namibia, and Swaziland;
while HIV infections in pregnant women appear to be stabilizing
at lower levels in Malawi, Zambia, and Zimbabwe, albeit with
little evidence of an impending decline. 16 The UNAIDS and WHO
report that
newly published study findings show southern Africa to be
firmly in the grip of the AIDS epidemic, as more people
succumb to HIV-related illnesses and die. Life expectancy at
birth has dropped below [forty] years in nine African
countries-Botswana, Central African Republic, Lesotho,
Malawi, Mozambique, Rwanda, Swaziland, Zambia, and
Zimbabwe. 17
Angola, according to UNAIDS and WHO, is an exception in the
Southern African region because "during nearly two generations of
war, civilians' movements were restricted, transport links severed,
and parts of the country were intermittently cut off from the
outside world."'1
8
In East Africa, data from some countries show signs of decline
in HIV infection levels. In Uganda, for example, national
prevalence fell from 13% in the early 1990s to 4.1% at the end of
2004.'9 HIV prevalence in Kenya and Burundi has also been
reported to be declining. 20  However, in other East African
countries: Ethiopia, Madagascar, and Tanzania, in particular, there
is no evidence of decline in HIV prevalence.2' In West Africa, the
HIV epidemic appears to have stabilized in most countries.
According to UNAIDS and WHO "overall, HIV prevalence is
lowest in Sahel countries and highest in Burkina Faso, Cote
d'Ivoire, and Nigeria. . . . Serious epidemics are underway in
Central Africa, with Cameroon and the Central African Republic
worst-affected., 22 Senegal, the often-celebrated HIV success story
in West Africa, is slowly witnessing a rising level of HIV
15 Id. at 23.
16 Id. at 23-24.
17 Id. at 25.
18 Id. at 24.
19 Id.
20 Supra note 14, at 24 (2004).
21 Id. at26.
22 Id. at 27-28.
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infection, especially among commercial sex workers.23 Compared
with other regions of the world, Africa's HIV/AIDS prevalence
rate is an unfair and disproportionate share of an estimated 40
million people living with HIV/AIDS globally.
The HIV/AIDS prevalence levels, albeit largely based on the
national surveys by most of the African countries themselves,
remain problematic largely because, as acknowledged by UNAIDS
and WHO, many African countries do not have reliable disease
mortality and morbidity data on ailments, clinical cases, hospital
admissions, or even causes of death. Most developing countries
do not have accurate mortality statistics, morbidity and quality-of-
life information, infant mortality rates, disease prevalence rates,
and core surveillance structures for a comprehensive
understanding of the burdens of disease that they face.24 Thus, the
data used by multilateral institutions to calculate prevalence rates
of HIV/AIDS in most of Africa are, at the very best, estimates.
Given the high morbidity and mortality burdens of AIDS in most
developing and under-developed countries, it is important to note
that AIDS, albeit not curable, can be treated with anti-retroviral
drugs.25  In what ways, therefore, have the normative
developments on intellectual property protection for
pharmaceutical patents at the WTO advanced or impeded access to
AIDS treatment in regions of the world with the highest number of
HIV/ADS cases? To explore this question, the next section
focuses on WTO and TRIPS.
III.The WTO, TRIPS, and Access to Essential Medicines for
HIV/AIDS
The tension between the logic of free trade and promotion of
public health is nowhere more apparent than in TRIPS. The
establishment of the WTO witnessed a supersonic expansion of
global trade and its regulation from goods to areas such as
23 Id. at 27.
24 William Foege, Foreword to GLOBAL BURDEN OF DiSEASE, at xxv, (C.J.L Murray
& A. Lopez eds., 1996)
25 James Thuo Gathii, Construing Intellectual Property Rights and Competition
Policy Consistently with Facilitating Access to Affordable AIDS Drugs to Low-End
Consumers, 53 FLA. L. REV. 727, 733-37 (2001) (stating that while AIDS is incurable, it
is highly a treatable disease).
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services, and intellectual property.26 As Kamal Malhotra observed,
The transformation of the General Agreement on Tariffs and
Trade (GATT) into the WTO in 1995 marked a paradigm shift,
resulting in significant differences between the two regimes.
The GATT system was primarily about negotiating market
access for traded goods. But the WTO's extension into new
substantive areas, intrusiveness into domestic policy-making,
'single undertaking' mandate, explicit linkage of trade with the
protection of investment and intellectual property rights, and
strict enforcement of disputes and cross-retaliation have
extended its authority into areas of domestic regulation,
legislation, governance and policy-making central to the
development process.27
Membership in the WTO automatically commits member-
states not just to liberalize trade in goods but also to make specific
policy choices on services, investment and intellectual property.
These commitments affect human development and public goods,
especially in developing countries with very weak governance
institutions for employment, education, public health, movements
of capital and labour, and ownership of and access to technology.28
Because of the monumental influence of the WTO in global
economic relations between countries, and the rules-based global
trade regime, it is now perceived that economic globalization
either constrains the capacity of the state to finance social safety
nets (public goods)29 or contributes in very complex ways to
"democratic deficit."
30
TRIPS, which was one of the agreements annexed in the
26 For a history of international trade and the evolution of the WTO, see JOHN
JACKSON, THE WORLD TRADING SYSTEM: LAW AND POLICY OF INTERNATIONAL ECONOMIC
RELATIONS (1997); M. TREBILCOCK & ROBERT HOWSE, THE LEGAL REGULATION OF
INTERNATIONAL TRADE (2001).
27 Kamal Malhotra, MAKING GLOBAL TRADE WORK FOR THE PEOPLE 3 (2003).
28 Id.
29 See generally Dani Rodrik, How Far Will International Economic Integration
Go? 14 J.EcON. PERSP. 177 (2000); Dani Rodrik, Governance of Economic
Globalization, in GOVERNANCE IN A GLOBALIZING WORLD 347 (Joseph S. Nye & John D.
Donahue eds., 2000); JOHN HILARY, THE WRONG MODEL: GATS, TRADE LIBERALISATION
AND CHILDREN'S RIGHT TO HEALTH (2001), http://www.savethechildren.
org.uk/temp/scuk/cache/cmsattach/986_wrongmodel.pdf.
30 Robert Howse, How to Begin to Think About the "Democratic Deficit" at the
WTO, (unpublished draft on file with author) http://faculty.Iaw.umich.edu/rhowse/
Drafts-andPublications/howse7.pdf (2003).
[VOL. 31
2006] HUMAN RIGHTS, PUBLIC HEALTH, AND PATENTS
Marrakesh Agreement that established the WTO in 1995, covers
both aspects of intellectual property rights: literary and artistic
property (copyrights and neighboring rights), and industrial
property.3' TRTPS seeks to harmonize certain aspects of
intellectual property rights at the global level. It sets a minimum
standard of intellectual property protection for all WTO member
states' national legislation. Although TRIPS directly and
indirectly codified flexibilities found on age-old practices of
parallel imports, 32  and compulsory licensing3 3 in intellectual
property law, legitimate efforts by a few developing countries to
pursue these measures in the face of high prevalence of HIV/AIDS
among their populations were either blocked or legally challenged
by some industrialized member-states of the WTO, especially by
the United States.34
The well-publicized dispute between leading pharmaceutical
companies supported by the United States and South Africa, and
the lingering disagreements between United States and Brazil are
cases in point.35 In 1998, forty pharmaceutical companies filed a
31 Industrial property rights include trademarks, patents, geographical indications,
industrial designs, and trade secrets. Patent protection for pharmaceuticals is set for a
minimum of twenty years.
32 Parallel imports allow for the importation of patented products without the
authorization of the patent holder. Parallel importation allows a country to "shop
around" for lower prices of the same patented product anywhere it may be found in the
global market. Article 6 of TRIPS codifies a well known principle of patent law known
as "exhaustion of rights." An intellectual property right is exhausted once the patented
product is marketed the first time with the consent of the patent owner. States can take
any action they deem fit at the point of exhaustion. TRIPS, supra note 5, art. 6.
33 Compulsory licensing allows a government to authorize local firms to produce
generic versions of patented drugs. It is often used during emergencies. TRIPS did not
expressly mention the term "compulsory license," but refers in Art. 31 to "other use of
the subject matter of the patent without the authorization of the right holder" in a number
of conditions including "national emergenc[ies]", and "other circumstances of extreme
urgency." Id. art. 31.
34 For an insightful and profound analysis of both the direct and indirect challenges
of these practices by industrialized countries, see Caroline Thomas, Trade Policy and the
Politics of Access to Drugs, 23 THIRD WORLD Q. 251 (2002); Naomi A. Bass, Note,
Implications of the TRIPS Agreement for Developing Countries: Pharmaceutical Patent
Laws in Brazil and South Africa in the 21' Century, 34 GEO. WASH. INT'L. L. REV. 191
(2002); Ellen t' Hoen, TRIPS, Pharmaceutical Patents, and Access to Essential
Medicines: A Long Way from Seattle to Doha, 3 CHI. J. INT'L. L. 27 (2002); Susan K.
Sell, The Quest for Global Governance in Intellectual Property and Public Health:
Structural, Discursive, and Institutional Dimensions, 77 TEMP. L. REV. 363 (2004).
35 For a discussion of the South Africa and Brazil cases, see Bass, supra note 34;
N.C. J. INT'L L. & COM. REG.
law suit against the government of South Africa, claiming among
others, that the South African Medicines and Related Substances
Control Amendment Act of 1997 violated the TRIPS agreement.
36
Commenting on this dispute, Ellen t'Hoen stated that the amended
Act "introduces a legal framework to increase the availability
of affordable medicines in South Africa" 37 through "generic
substitution of off-patent medicines, transparent pricing for all
medicines, and the parallel importation of patented medicines. 38
Brazil has long been cited not only as a success story but also as a
model developing country. The United States launched a dispute
settlement process against Brazil at the WTO in 2001 alleging that
Article 68 of the Brazilian intellectual property law that requires
all patent holders in Brazil to manufacture their product in Brazil
violates Articles 27 and 28 of TRIPS. Under Brazilian intellectual
property law, failure by a patent holder, unless he proves that it is
economically unfeasible or unreasonable, to produce the patented
product in Brazil could trigger compulsory license by the
government to manufacture the product locally. 39  In both the
South African and Brazilian cases, global civil society activism
and advocacy targeted at the WTO, the pharmaceutical companies,
and their home governments led to the withdrawal of the law suit
in South Africa, and the U.S. complaint against Brazil at the
WTO.40
At least two important lessons should be learned from the
South African and Brazilian cases on the challenges to exploiting
public health flexibilities in TRIPS. First, the law suit against
South Africa by forty pharmaceutical companies set a despicable
precedent by which corporations, mostly incorporated in South
Africa as subsidiaries of their parent companies, could sue a
t'Hoen, supra note 34.
36 Stephen Marks, Health and Human Rights: The Expanding International
Agenda, AM. SOC. INT'L. L. PRO. 64 (2001) (stating that the pharmaceutical companies
that filed the suit were among the world's largest even though "governments and
activists around the world are supporting the right of South Africa and other countries
faced with poverty and the devastating ravages of the AIDS epidemic to import or
manufacture generic versions of the AIDS treatment drugs at a fraction of the price the
pharmaceuticals charge").
37 t'Hoen, supra note 34, at 30.
38 Id.
39 For analysis of the patent law in Brazil in this context, see id.; Bass, supra note
34.
40 Bass, supra note 34.
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sovereign government claiming rights and benefits under TRIPS,
an international treaty accepted or ratified exclusively by states as
members of the WTO.4  Second, the attitude of the U.S.
government is hypocritical. The United States was willing, and in
fact threatened, to issue compulsory license to produce and
stockpile Cipro during the bioterrorist threats posed by anthrax
deaths shortly after the September 1 1th terrorist attacks. This
forced the German company Bayer that had a patent on Cipro to
sell the drug to United States and Canada at heavily discounted
prices." This is exactly what South Africa sought to do with
respect to ARV drugs for the epidemic of HIV/AIDS in South
Africa. Sarah Joseph's well founded observation on the emergency
posed to the United States and Canada by anthrax and that posed
to South Africa by AIDS can hardly be faulted:
It is interesting to note how quickly the United States and
Canada were to threaten the Bayer patent, and how quick were
media commentators to question Bayer's profit margin on Cipro,
at a time when the United States had thirteen anthrax cases with
three deaths, and Canada had no cases at all. The North
American anthrax scare was not an emergency on a par with the
devastating effects of HIV/AIDS in the developing world. The
North American response to the anthrax scare was probably
legitimate in the circumstances. However it displayed blatant
hypocrisy on the part of the West regarding the acceptability of
patent relaxation in the context of health emergencies which
confront "us," and in the context of health emergencies which
constantly confront "them" in the developing world.43
41 One wonders if, conversely, the South African government or any other
developing country could sue a corporation claiming benefits for a breach of an
international treaty obligation.
42 For perspectives on the threat by the U.S. government to issue compulsory
licenses to override Bayer's patent on Cipro, see David B. Resnik & Kenneth A. De
Ville, Bioterrorism and Patent Rights: "Compulsory Licensure" and the Case of Cipro,
2 AM. J. OF BioETHics 29 (2002); Divua Murphy, The Future of Compulsory Licensing:
Deciphering the Doha Declaration on the TRIPS Agreement and Public Health, 17 AM.
U. INT'L. L. REV. 1299, 1314-1315 (2002).
43 Sarah Joseph, Pharmaceutical Corporations and Access to Drugs: The "Fourth
Wave" of Corporate Human Rights Scrutiny, 25 HUM. RTS. Q. 426, 446-47 (2003). For
other perspectives on the threat by the U.S. government to issue compulsory licenses to
override Bayer's patent on Cipro, see David B. Resnik & Kenneth A. De Ville,
Bioterrorism and Patent Rights: "Compulsory Licensure" and the Case of Cipro, 2 AM.
J. OF BIOETHICS 29 (2002); Divya Murphy, The Future of Compulsory Licensing:
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As the debate on the public health flexibilities in the TRIPS
agreement raged, on November 14, 2001, after prolonged agitation
by developing countries and sustained advocacy by a coalition of
civil society groups, the WTO ministerial conference in Doha,
adopted the Declaration on the TRIPS Agreement and Public
Health.' The Declaration affirmed that TRIPS can and should be
interpreted and implemented in a manner supportive of WTO
Members' right to protect public health, and in particular, to
promote access to medicines for all.45 The Declaration recognized
that WTO Members with insufficient or no manufacturing
capacities in the pharmaceutical sector could face difficulties in
making effective use of compulsory licensing under the TRIPS
Agreement.46 On August 30, 2003, the General Council of the
WTO adopted a decision on the Implementation of Paragraph 6 of
the Doha Declaration on the TRIPS Agreement and Public
Health. 47  The decision provides for the criteria aimed at
facilitating access to essential medicines, including anti-retrovirals
for HIV/AIDS, by vulnerable populations in the least developed
and developing countries. Despite the WTO General Council
Decision in 2003, difficult questions still remain on the best ways
to maximize access to essential medicines, especially anti-
retroviral drugs for HIV/AIDS. While the Decision imposes
certain key obligations on exporting and importing countries for
these medicines, only two industrialized countries, Canada and
Norway, have initiated legislative changes to their national patent
laws to allow domestic production of generic drugs for export to
poor countries hit by HIV/AIDS and other diseases.48 The
Deciphering the Doha Declaration on the TRIPS Agreement and Public Health, 17 AM.
U. INT'L. L. REv. 1299, 1314-15 (2002).
44 World Trade Organization Doha Declaration on TRIPS Agreement and Public
Health, Nov. 20, 2001, WT/MIN(01)/DEC/ 2,41 I.L.M. 755 (2002) [hereinafter Doha
Declaration]. On the legal status of the Doha Declaration, see James Thuo Gathii, The
Legal Status of the Doha Declaration on TRIPS and Public Health Under the Vienna
Convention on the Law of Treaties, 15 HARV. J. L. & TECH. 291 (2002).
45 Doha Declaration, supra note 44.
46 Id., 4.
47 General Council Decision, Implementation of Paragraph 6 of the Doha
Declaration on the TRIPS Agreement and Public Health, WT/1U540 (Sept. 1 2003),
http://www. wto.org/english/tratop-e/trips-e/implem-para6_e.htm.
48 In June 2004, the Canadian legislature passed Bill C-9, which was an Act to
amend both the Patent Act and Food and Drugs Act, now enacted as the Pledge to Africa
Act. The new legislation is meant to facilitate access to essential medicines by
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Decision imposes an obligation on developing countries to notify
the WTO of an intention to become an eligible importing member,
and to notify the WTO specifically about the products and
quantities.4 9
About 80% of developing countries lack a functional
pharmaceutical sector with a capacity for domestic production of
anti-retroviral drugs.5° As a result, these countries cannot issue
compulsory license for domestic production of generic HIV/AIDS
drugs simply because they lack the capacity and technology to do
so. The only option for many of these countries remains a dual
process that involves importing generics from an industrialized
country that is willing to amend its patent legislation to produce
generic drugs solely for export to countries in most need of them.
But can industrialized countries withstand the pressure and
corporate lobby by the pharmaceutical industry? If there is one
lesson to learn from the TRIPS negotiations in the 1990s, it is that
the industry lobby remains very influential and powerful in
international economic relations. As Scott Sinclair observed,
"corporate pressure is nothing new in WTO negotiations. Such
pressure, largely exerted by U.S-based firms, is widely
acknowledged to have been a driving force in the negotiations."51
The entire gamut of international trade and global economic
relations is now shaped by the "neo-liberal dogma of minimizing
intrusions on the market, and 'downsizing' the role of government
in relation to the provision of public goods that compose the social
agenda. ' 52 Promotion of human rights and human dignity; public
health and access to essential medicines; respect for the
environment, and protection of environmental rights, all come with
authorizing Canadian generic pharmaceutical companies to produce generic drugs in
Canada for export to developing countries that lack their own domestic production
capacity. See Pledge to Africa Act, S.C. 2004, c.23.
49 For a good discussion of the challenges of implementing the WTO General
Council Decision, see Carlos Correa, Implementation of the WTO General Council
Decision on Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public
Health, http://www.who.int/medicines/areas/policy/WTO-DOHADecisionParolefinal.
pdf.
50 Id.
51 SCOTr SINCLAIR, GATS: How THE WORLD TRADE ORGANIZATION'S NEW
SERVICES NEGOTIATIONS THREATENS DEMOCRACY 2 (2000).
52 Richard Falk, The Coming Global Civilization: Neo-Liberal or Humanist, supra
note 3, at 15.
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this social agenda. The establishment of the WTO has challenged
the actors in global governance (both states and non-states) to take
the task of balancing neo-liberal ideology with the promotion of
global public goods 53 seriously.
IV. Assessing Public Health Fingerprints in Global Trade
Regime
The rules-based international trade architecture, firmly
anchored on the institutional pillars of the WTO, has developed a
list of powerful norms against which public good like public
health policies are measured. These norms, based mainly on
National Treatment and Most Favored Nation (MFN) principles,
add up to the grand rule of non-discrimination in international
trade.54 There is a certain level of agreement between proponents
and critics of trade liberalization that international trade is
necessary, but how then should free trade respond to the
imperatives of human dignity-human rights, environmental
protection, and public health (public goods)? Since the General
Agreement on Tariffs and Trade (GATT) 1947, international trade
governance frameworks have grappled with the task of reconciling
trade liberalization and national protection of public health and
other public goods. 5 Article XX (b) of GATT56 provides:
Subject to the requirement that such measures are not applied in
a manner which would constitute a means of arbitrary or
53 On the concept of public goods in the global economy, see GLOBAL PUBLIC
GOODS: INTERNATIONAL COOPERATION IN THE 21ST CENTURY (Inge Kaul et al. eds.,
1999); see also PROVIDING GLOBAL PUBLIC GOODS: MANAGING GLOBALIZATION (Inge
Kaul et al. eds., 2003). On aspects of public health as global public goods, see GLOBAL
PUBLIC GOODS FOR HEALTH: ECONOMIC AND PUBLIC HEALTH PERSPECTIVES (Richard D.
Smith et al. eds., 2003).
54 Under MFN obligation, countries cannot discriminate between their trading
partners. General Agreement on Tariffs and Trade, Oct. 30, 1947, 61 Stat. A-11, 55
U.N.T.S. 194 [hereinafter GATT]. A special treatment granted to one country has to be
granted to all WTO Members. National Treatment requires that imported and locally-
produced goods be treated equally, in terms of competitive opportunities in the importing
country's market. Id. art. 3.
55 Id.
56 Part of GATT 1947 became GATT 1994 at the end of Uruguay Round of trade
negotiations that led to the establishment of the WTO. General Agreement on Tariffs and
Trade 1994, Apr. 15, 1994, Marrakesh Agreement Establishing the World Trade
Organization, Annex 1A, THE LEGAL TEXTS: THE RESULTS OF THE URUGUAY ROUND OF
MULTILATERAL TRADE NEGOTIATIONS 17 (1999), 1867 U.N.T.S. 187, 33 I.L.M. 1153
(1994) [hereinafter GATT 1994].
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unjustifiable discrimination between countries where the same
conditions prevail, or a disguised restriction on international
trade, nothing in this Agreement shall be construed to prevent
the adoption or enforcement by any contracting party of
measures: necessary to protect human, animal or plant life or
health.57
This delicate balance, albeit provided in similar but different
language in other trade Agreements,58 raises some serious
conundrums in interpretation. To make use of the health
exceptions, WTO Agreements generally require that the health
measures adopted by a country be no more restrictive than
necessary. Relying on the WTO Appellate Panel decision in the
Asbestos Case,5 9 the WTO and WHO secretariats, in a joint study,
observed that human health has been recognized by the WTO as
being important in the highest degree.6" However, going by the
precedents of GATT and WTO jurisprudence, national measures
adopted by countries to protect public health are subjected to
very strict scrutiny against immutable trade norms of non-
discrimination as driven by principles of MFN, National
Treatment, and Elimination of Quantitative Restrictions.6' A
typical WTO trade panel would determine first if the public health
policy in question is "necessary," and if other non-trade restrictive
alternative measures could be used to achieve the public health
purpose. In this interpretive paradigm, trade therefore takes
precedence over national public health measures. Two precedents
in international trade law, the first under the GATT, and the
second under the WTO, illustrate this point.
57 Id.
58 See General Agreement on Trade in Services, Apr. 15, 1994, Marrakesh
Agreement Establishing the World Trade Organization, Annex lB, THE LEGAL TEXTS:
THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS 284
(1999), 1869 U.N.T.S. 183, 33 I.L.M. 1167 (1994) [hereinafter GATS].
59 Appellate Body Report, Canada v European Communities/France-Measures
Affecting Asbestos and Asbestos-Containing Products, WT/DS135/AB/R (March 12,
2001) (01-1157).
60 WHO & WTO, WTO Agreements and Public Health: A Joint Study by the WHO
and the WTO Secretariat 31 (2002). However, based on the predominant cases on
Trade-Public Health disputes, this finding is doubtful.
61 See GATT, supra note 54 for rule against quantitative restrictions international
trade.
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In the Thai Cigarettes62 dispute between United States. and
Thailand under the GATT, Thailand, pursuant to its 1966 Tobacco
Act, prohibited the importation of cigarettes and other tobacco
products into Thailand, but authorized the sale of domestic Thai
cigarettes. The United States challenged the ban on imports of
cigarettes into Thailand as a violation of General Elimination of
Quantitative Restrictions in Article XI of the GATT.63 Thailand
defended the ban as a measure under Article XX(b) "necessary"
for the protection of public health. While no comparable ban
existed on domestic Thai cigarettes, Thailand argued that
American cigarettes were more likely to induce women and young
persons to smoke because of sophisticated advertising directed at
these groups. Thailand also argued that American cigarettes were
more addictive or more likely to be consumed in larger quantities
than comparable Thai cigarettes due to their higher nicotine and
chemical contents. The GATT panel ruled that an import ban
would only be necessary for public health reasons within Article
XX(b) exceptions if alternative non-trade restricting measures
could not be used to achieve the public health objectives in
question. The panel found that import restrictions were not
"necessary" because other less trade-restrictive tobacco control
measures could be used to protect public health on a non-
discriminatory basis to both domestic and imported cigarettes.
In the Beef Hormones64 dispute between United States/Canada
and the European Community, following concerns by European
consumer groups over the use of growth promotion hormones in
livestock, the WHO-Food and Agriculture Organization Joint
Expert Committee examined the use of these hormones and their
health implications. On the basis of recommendations of the
expert committee, the Codex Alimentarius Commission adopted
standards for five of the growth-promoting hormones.65 The
62 Report of the Panel, Thailand-Restrictions on Importation of and Internal
Taxes on Cigarettes ,DSIO/R, BISD 37S/200 (Nov. 7, 1990) [hereinafeter Thai
Cigarette].
63 GATr, supra note 54, art. 11.
64 WTO Panel Decision, European Communities- Measures Concerning Meat and
Meat Products (Hormones), Complaint of the United States, WT/DS26/R/USA, (Aug.
18, 1997).
65 The Codex Alimentarius Commission was established in 1962 and is jointly
governed by the Food and Agriculture Organization of the United Nations (FAO) and the
World Health Organization (WHO). It has a mandate to protect the health of consumers
and ensure fair practices in food trade by standards for food safety. FAO.org, The Codex
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standards specified the maximum level of hormone residues in
foods that are safe for human consumption. The European Union,
following concerns raised by consumer groups on continued use of
illegal hormonal substances, imposed a complete ban on the use of
growth-promoting hormones in 1988. In January 1996, the United
States (followed by Canada in June 1996) challenged the European
Union ban as a violation of the WTO's Sanitary and Phyto-
sanitary Measures (SPS) Agreement.66 In 1988, the Appellate
Body of the WTO ruled that the EU's ban violated the SPS
Agreement. Since the International Codex standards existed for
five out of the six hormones at issue, the Appellate Body ruled that
the EU ban violated the SPS Agreement because it was not based
on risk assessment. 67 Although the Appellate Body confirmed the
rights of WTO Members to have the level of health protection they
want, even above international standards, this decision subjects
such national measures to scientific evidence and risk assessment,
which would likely impose onerous burdens, particularly on
developing countries.
The task of protecting and promoting human health through
domestic measures in an era of global economic integration is
well illustrated in the Thai Cigarette and the Beef Hormones
cases. Even in the Asbestos Case (Canada v. European Community
and France), and the Reformulated Gasoline Case68 (Brazil and
Venezuela v. United States) where the WTO Appellate Bodies
upheld Article XX(b) health measures, the dispute settlement
bodies did so after subjecting those measures to rigorous scrutiny
against immutable trade principles.69 Had the Panels found those
measures discriminatory or trade-restrictive, they would have ruled
that they either violated National Treatment or were inconsistent
with the requirements of the chapeau of Article XX.
V. Epilogue: Human Rights, Public Health, and Free Trade--
system: FAO, WHO and the Codex Alimentarius Commission,
http://www.fao.org/documents/show-Cdr.asp?url-file=////docrep/w9Il4efW9114e04.htm
66 Appellate Body Report, European Communities-Measures Concerning Meat
and Meat Products (Hormones), WT/DS26/AB/R, WT/DS48/AB/R (Jan. 16, 1998).
67 Id.
68 Appellate Body Report, United States-Standards for Reformulated and
Conventional Gasoline, WT/DS2/AB/R (Apr. 29, 1996).
69 Id.
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Towards Policy Coherence in Global Governance
The intense "life versus profit" debate that has dominated the
WTO TRIPS regime has achieved one useful thing: it has placed
public health and the human right to health firmly on the global
governance agenda. Human rights and public health searchlights
will now beam on neo-liberal institutions like the WTO as well as
non-state actors like the transnational pharmaceutical industry.
International law, since the birth of the United Nations in 1945, is
replete with human rights instruments, customary, and treaty law.
A significant percentage of these instruments codify aspects of the
right to health in very clear and concise language.7 ° But as rightly
observed by Robert Howse and Makau Mutua,
[riegional and multilateral investment agreements have
proceeded without credible efforts to conceptually and
practically address their impacts on legally protected human
rights... Trade and investment agreements.. .must be held
accountable to existing human rights law.7'
In the event of a conflict between human rights guaranteed in
an international covenant, and a provision of international trade
agreement like TRIPS, which one should take precedent over the
other? Should human rights "trump" trade or vice versa? Will
international law develop a body of rules that advances free trade
while at the same time promoting and protecting human rights? 72
The challenge before the global governance today is, as Robert
Howse and Makau Mutua observed, "how to influence the process
70 For insightful discussion of the norms of human rights as they relate to health,
see Sarah Joseph, Pharmaceutical Corporations and Access to Drugs: The "Fourth
Wave" of Corporate Human Rights Scrutiny 25 HuM. R. Q. 425 (2003); Virginia Leary,
The Right to Health in International Human Rights Law I HEALTH & HUM. R. 25
(1994); Phillip Cullet, Patents and Medicines: The Relationship Between TRIPS and the
Human Right to Health, 79 INT'L AFF. 139 (2003); Katarina Tomaseveski, Health,
UNITED NATIONS LEGAL ORDER, 859 (Oscar Schachter & Christopher C. Joyner eds.,
1995); B. Toebes, Towards an Improved Understanding of the International Human
Right to Health, 21 HUM. R. Q. 661 (1999); OBIJIOFOR AGINAM, GLOBAL HEALTH
GOVERNANCE: INTERNATIONAL LAW AND PUBLIC HEALTH IN A DIVIDED WORLD 35-40
(2005). For some progressive insights from the United Nations Special Rapporteur on
Right to Health, see The Right of Everyone to the Enjoyment of the Highest Attainable
Standard of Physical and Mental Health, (Feb. 13 2003),
http://www.unhchr.ch/Huridocda/Huridoca.nsf/0/5f07e25ce34edd01 ci 256ba60056deff?
Opendocument.
71 ROBERT HOWSE & MAKUA MUTUA, PROTECTING HUMAN RIGHTS IN A GLOBAL
ECONOMY: CHALLENGES FOR THE WORLD TRADE ORGANIZATION 6 (2000).
72 Id. at 7
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of globalization in such a way that human suffering, poverty,
exploitation, exclusion, and discrimination are eliminated. Since
trade is the driving engine of globalization, it is imperative that, at
the very least, rules governing it do not violate human rights but
rather promote and protect them.
'
,
73
Given the jurisprudence of the WTO as exemplified in cases
like Thai Cigarettes and Beef Hormones, an apparent inconsistency
between public goods (including health, environmental, and
human rights) and principles of free trade is often resolved in favor
of free trade if the domestic policy in question is found to be
discriminatory or protectionist. The norm of non-discrimination
solidly founded on National Treatment and MFN runs through the
entire gamut of WTO agreements.74 At the global level, the
WTO's policies that support free trade and intellectual property
rights seem to impede WHO's policy on the promotion of
universal access to "essential medicines"75 and the right of
everyone to the highest attainable standard of physical and mental
health.
I propose three possible scenarios to resolve this tension in the
future, especially for developing countries. First, I suggest that
countries that have the technology should pursue the Brazilian
model of domestic production of generic drugs to address the
humanitarian catastrophe of HIV/AIDS, and other prevailing
health problems like malaria. Following the Brazilian model will
allow these countries to meet the human rights and public health
needs of their populations without violating TRIPS. Second,
because not all countries have provisions on right to health in their
constitutions as a justiciable human right (just like the South
African constitution), I suggest that a robust/activist interpretation
of the right to life is needed as a pathway to ultimately getting the
right to health and other social, economic and cultural rights:
73 Id.
74 See GATr, supra note 54. See generally Marrakesh Agreement Establishing the
World Trade Organization, Annex IA, The Legal Texts: The Results of the Uruguay
Round of Multilateral Trade Negotiations 17 (1999), 1867 U.N.T.S. 187, 33 I.L.M. 1153
(1994).
75 WHO defines essential medicines as "those medicines that satisfy the health care
needs of the majority of the population; they should therefore be available at all times in
adequate amounts and in the appropriate dosage form." See World Health Organization,
Globalization and Access to Drugs: Perspectives on the WTO/FRIPS Agreement 10
(1999), http://who.int/medicines/areas/policy.who-dap-98_9rev.pdf.
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housing, food, and education. In other words, access to essential
drugs must be construed within the right to life. The dichotomy
between civil and political rights, and economic, social and
cultural rights will begin to dissipate based on the indivisibility of
all rights. Third and most importantly, I suggest the need for a
robust and feasible project on "policy coherence" domestically and
internationally. Since trade agreements affect public health and
human rights in complex ways, trade ministers and bureaucrats
must talk with their health colleagues to do a "human rights and
public health impact assessment" of free trade agreements. This
will minimize the negative impact of trade agreements on health
and human rights. Internationally, the relevant multilateral
institutions, in this case, WTO and WHO, should also assess the
commonalities and tensions across their respective mandates.
Although the WTO is not part of the United Nations family of
organizations, the rationale for international policy coherence for
the organizations within the United Nations system is well
captured by Judge Weeramantry's dissenting opinion:
The United Nations family of organizations today is widely
expanded, closely knit, and works together, in developing areas
of international activity, within the framework of the
international rule of law. While each of these organizations has
its specific functions, they all interlock in the common service of
the ideals of the United Nations and they all operate under the
common aegis of international law. Though each of them is
given a particular sphere of activity, they do not necessarily
function in closed compartments, for the complex nature of
United Nations activities may often result in overlapping areas
of interest. The work of one organization may interweave with
that of other organizations, and hence would have repercussions
on the work of other members of the United Nations family.76
In the Nuclear Weapons opinion, the ICJ ruled that constituent
instruments of international organizations, in this case the
Constitution of the World Health Organization, are treaties in
international law.77 The interpretation of these constituent
instruments requires the application of the relevant provisions of
the Vienna Convention on the Law of Treaties. Since the
76 Legality of the Use By a State of Nuclear Weapons in Armed Conflict, 1996
I.C.J. 94 (July 8, 1996) (Weeramantry, dissenting) [hereinafter Nuclear Weapons].
77 Id. at 75.
78 Id.
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majority of the WTO member states are also member states of the
WHO, and the WHO was founded decades before the WTO, the
key obligations undertaken by states as signatories to WHO
Constitution cannot be derogated by mere membership of the
WTO that carries with it acceptance of trade agreements that
appear inconsistent with the codification of the right to the highest
attainable standard of health in the WHO Constitution.
The trade-health tension in global governance is therefore not
as simplistic as saying that globalization is inherently bad or
innately good, especially given the asymmetry and social
inequalities and disparities between countries. What is needed
first is a supportive environment for the weaker nation-states
(especially the developing countries) to strengthen their
institutional capacity to generate and promote public goods, taking
into account each country's present specific social and economic
conditions. This is the only time when agreements like TRIPS
will be humane. The extent to which this would likely occur
largely depends on whether the neo-liberal dogma of the free trade
will, instead of continuing to champion a corporate agenda, focus
on the humanization of the norms of economic globalization
through the protection of public goods and the promotion of
human dignity.
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